Overview

* Wave Life Sciences ( WVE ) Q3 revenue and net income missed analyst expectations

* Company maintains strong cash position, extending runway into Q2 2027

* WVE-007 and WVE-006 clinical programs advance, achieving key objectives

Outlook

* Wave expects multiple clinical data updates from INLIGHT trial in 2025 and 2026

* Company plans to file NDA for WVE-N531 in 2026

* Wave plans IND application for WVE-003 Phase 2/3 study in 2H 2025

Result Drivers

* R&D - Expenses were $45.9 million in the third quarter of 2025 as compared to $41.2 million in the same period in 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $7.61 $11.13

Revenue mln mln (15

Analysts

)

Q3 EPS -$0.32

Q3 Net Miss -$53.85 -$49.55

Income mln mln (14

Analysts

)

Q3 Miss -$56.35 -$51.47

Income mln mln (14

from Analysts

Operatio )

ns

Q3 Miss -$53.85 -$49.19

Pretax mln mln (13

Profit Analysts

)

Q3 $63.96

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for WAVE Life Sciences Ltd ( WVE ) is $19.00, about 58.6% above its November 7 closing price of $7.86

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)